Nascent Biotech

Nascent Biotech is a public, clinical-stage biotechnology company focused on developing human antibody and cytokine-based therapies for cancer. Its core strategy is to mimic the body's natural, multi-targeted immune response by combining selected biomolecules into therapeutic 'cocktails,' a departure from standard single-agent monoclonal antibody approaches. The company's lead candidate, Pritumumab, has completed Phase I safety studies and is preparing for pivotal Phase II trials in orphan-designated cancers, representing a critical inflection point. However, the company faces significant financial and operational challenges, including a delisting from the OTCBB as it seeks capital to fund its next development phase.

A drug discovery platform that leverages the natural human immune response to identify novel antibodies and antigens, with a strategy to mimic the body's oligoclonal response by combining selected antibodies and cytokines into multi-targeted therapeutic 'cocktails.'

Operates in the crowded and competitive oncology antibody space, but differentiates through a novel, naturally derived antigen target and a 'cocktail' therapeutic strategy. Faces competition from standard-of-care, approved biologics, and numerous novel modalities in development for glioblastoma and pancreatic cancer.